ArticleJournal of ginseng research2025
Ginsenoside Re promotes osteogenic differentiation via BMP2/p38 pathway
Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nutritional supplementation withFrontiers in nutrition · 2026Pooled it
- Activation of BMPR1b-SMAD pathway by Ginsenoside F1 restores osteoblast function in ovariectomy-induced osteoporosis.Journal of ginseng research · 2026Article
- Induced membrane-mediated DBM in combination with PRP: an autologous bone graft substitute therapy with remarkable osteoformation potency for challenging bone defects.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ginsenosides have been used in traditional Chinese medicine to treat fractures. Ginsenoside Re, a key component of P. ginseng, however, the molecular mechanisms underlying these effects remain inadequately understood. This study aims to investigate the effects of Ginsenoside Re on bone formation in fractures and to explore the underlying molecular mechanisms involved. Methods: Cell proliferation and osteogenic differentiation were evaluated using the Cell Counting Kit-8 (CCK-8) assay and alkaline phosphatase (ALP) staining, respectively. Quantitative PCR (qPCR) and western blotting were employed to quantify mRNA and protein expression levels. To assess bone formation Results: Ginsenoside Re promotes normal development and survival in zebrafish. In a zebrafish model, ginsenoside Re enhances bone regeneration, accompanied by upregulated expression of osteogenic markers. Following a 10-day treatment with 20 μM ginsenoside Re, mRNA sequencing (mRNA-Seq) analysis identified Conclusions: In conclusion, our findings demonstrate, for the first time, that ginsenoside Re at an optimal concentration of 20 μM enhances bone formation by modulating the osteogenic system. Mechanistically, we reveal that this pro-osteogenic effect is mediated through the BMP2/p38 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.